PSMD4 and hepatocellular carcinoma: In conclusion, our findings demonstrated that oncofetal MCB1 might not only act as a driver for HCC initiation and chemoresistance but also serve as a serum biomarker for individualized HCC therapy, which is worthy of further validation by clinical trials.